Cytochrome P450 reductase, antioxidant enzymes and cellular resistance to doxorubicin
Open Access
- 15 July 1990
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 40 (2) , 385-387
- https://doi.org/10.1016/0006-2952(90)90705-p
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Anthracycline resistance in murine leukemic P388 CELLSBiochemical Pharmacology, 1990
- Role of the Glutathione Redox Cycle in Acquired and de Novo Multidrug ResistanceScience, 1988
- Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells☆Cancer Letters, 1987
- Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell linesBiochemical Pharmacology, 1986
- Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletionBiochemical Pharmacology, 1985
- Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycinBiochemical Pharmacology, 1982
- Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivityBiochemical Pharmacology, 1982
- Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in ehrlich ascites tumour cellsBiochemical Pharmacology, 1978
- Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemiaBiochemical Pharmacology, 1978
- Adriamycin—A ReviewJNCI Journal of the National Cancer Institute, 1975